TMO
Thermo Fisher Scientific Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$608.30
−1.64%Sep 2, 2026, 12:30 UTC
Thermo Fisher Scientific launched the Thermo Scientific Multiskan Ease Absorbance Microplate Reader for protein, cell, and microbial analysis.
Source:Sep 1, 2026, 19:31 UTC
Thermo Fisher Scientific launched the EMPAD G2 detector, enhancing 4D STEM imaging speed, sensitivity, and workflow integration for its Analytical Instruments portfolio.
Source:Aug 27, 2026, 12:30 UTC
Thermo Fisher Scientific introduced the Thermo Scientific EMPAD G2 electron detector, designed for high-speed 4D scanning transmission electron microscopy to advance materials research.
Aug 25, 2026, 23:59 UTC
The University of Queensland and Thermo Fisher Scientific signed a Framework Agreement to collaborate on clean energy, advanced manufacturing, and biomedical science, including the establishment of an Indigenous Education Fund with a $50,000 donation from Thermo Fisher.
Source:Aug 21, 2026, 08:51 UTC
Bank of New York Mellon Corp acquired a new stake in Thermo Fisher Scientific Inc., purchasing 3,938,410 shares valued at approximately $1.97 billion, as disclosed in its 13F filing.
Source:Aug 19, 2026, 11:07 UTC
Shanghai Mayor Gong Zheng met with Thermo Fisher Scientific's chairman and CEO on August 19, 2026, to discuss deepening cooperation and the company's further investment in Shanghai's biomedical industry.
Aug 19, 2026, 04:30 UTC
Diageo appointed Alex Keith, former CEO of Procter & Gamble's beauty business, as a non-executive director.
Source:Aug 18, 2026, 00:07 UTC
Thermo Fisher Scientific appointed Dan Rosen as President of China, succeeding Miguel Faustino, effective in the fourth quarter of 2026.
Source:Aug 17, 2026, 08:57 UTC
Bryn Mawr Trust Advisors LLC acquired a new stake in Thermo Fisher Scientific Inc. during the second quarter of 2026, purchasing 4,936 shares valued at approximately $2,475,000.
Source:Aug 17, 2026, 08:57 UTC
Cornerstone Capital Inc. disclosed a new stake in Thermo Fisher Scientific Inc., purchasing 49,009 shares valued at approximately $24.57 million in the second quarter.
Source:Aug 17, 2026, 08:57 UTC
Bridgewater Advisors Inc. acquired a new position in Thermo Fisher Scientific Inc., purchasing 2,380 shares valued at approximately $1,366,000, as disclosed in its Form 13F filing with the SEC.
Source:Aug 13, 2026, 12:15 UTC
Vietnam's National Innovation Center (NIC) and Thermo Fisher Scientific agreed to cooperate on developing shared research and technology infrastructure in Vietnam, aiming to reduce technology access costs and strengthen the country's innovation ecosystem.
Source:Aug 12, 2026, 12:13 UTC
Astorg completed its acquisition of Thermo Fisher Scientific's global microbiology business, establishing an independent diagnostics company led by CEO Dirk Bontridder.
Jul 24, 2026, 12:30 UTC
Thermo Fisher Scientific launched the Thermo Scientific InstaFlux integrated media-on-demand enrichment workflow for food microbiology laboratories globally.
Source:Jul 23, 2026, 10:00 UTC
Thermo Fisher Scientific reported its second quarter 2026 financial results, with revenue of $11.99 billion, GAAP EPS of $4.68, and adjusted EPS of $6.03.
Jul 22, 2026, 06:32 UTC
ImmuPharma PLC appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment Kapiglucagon.
Jul 15, 2026, 15:45 UTC
San Diego Zoo Wildlife Alliance appointed Annie Fitzgerald as chief operating officer and Allyson Carr as chief human resources officer.
Source:Jul 9, 2026, 21:00 UTC
Thermo Fisher Scientific Inc. announced a quarterly cash dividend of $0.47 per common share, payable on October 15, 2026, to shareholders of record as of September 15, 2026.
Source:Jul 7, 2026, 12:30 UTC
Thermo Fisher Scientific received FBI approval for its RapidINTEL Plus Cartridge to generate DNA profiles eligible for national CODIS searches.
Source:Jul 2, 2026, 11:00 UTC
Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.
Source:Jul 2, 2026, 00:00 UTC
Arcturus Therapeutics signed a Master Services Agreement with Thermo Fisher Scientific for development services for ARCT-032, an mRNA therapeutic for cystic fibrosis, with Thermo Fisher contributing up to $40 million in clinical manufacturing services and Arcturus engaging PPD for up to $40 million in CRO services.
Jun 29, 2026, 08:07 UTC
genedrive PLC signed a collaboration agreement with Thermo Fisher Scientific to develop a high-throughput laboratory test.
Source:Jun 16, 2026, 00:00 UTC
GeneDx Holdings Corp. appointed Mark Gardner as President, effective June 15, 2026.
Source:Jun 1, 2026, 12:30 UTC
Thermo Fisher Scientific expanded its Orbitrap mass spectrometry platforms, AI-enabled software and integrated workflows at the ASMS 2026 conference.
Source: